B2M Knockout iPS Cell Line

Catalog #
82161
$7,350 *
Size: 1 vial
Qty
*US Pricing only. For international pricing, please contact your local distributor.
Purchase
Description

The B2M Knockout iPS Cell Line is an iPS cell line that has been edited using CRISPR/Cas9 technology to delete B2M (Beta-2-Microglobulin) gene expression. The B2M-targeting CRISPR/Cas9 editing agents were delivered via transduction with B2M (Human) CRISPR/Cas9 Lentivirus (Non-Integrating) (BPS Bioscience #78341).

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

Synonyms
iPSC
Product Info
Storage and Usage
Citations
Host Cell Line
Non-Disease Human iPS Cell Line (iXCells 30HU-002)
Supplied As
Each vial contains 2 x 106 cells in 1 ml of iPS Cell Freezing Medium
Materials Required But Not Supplied

Media Required for Cell Culture

Name Ordering Information
mTeSR™ Plus Stem Cell Technologies #100-0276
Matrigel™ Corning #354230
DMEM/F12 Thermo Fisher #11330032
Thiazovivin BPS Bioscience #78506
RelesR Stem Cell Technologies #05872
Accutase Thermo Fisher #A1110501
Mycoplasma Testing

The cell line has been screened to confirm the absence of Mycoplasma species.

Background

The discovery by Yamanaka and colleagues in 2007 that 4 factors were sufficient to reprogram terminally differentiated fibroblasts into pluripotent stem cells launched the advent of human induced pluripotent stem (iPS) cell technology. These human iPS cells are capable of both self-renewal and differentiation down all three germline lineages and provide both a tool to model human development and disease in the relevant differentiated human cell types, and a unique opportunity for high throughput drug screening and cell therapy development.

B2M (Beta-2-Microglobulin) forms a heteromeric complex with HLA-A, HLA-B and HLA-C molecules to generate the functional Class I MHC molecule responsible for antigen presentation to T-Cells. Class I MHC molecules are present on the surface of all nucleated cells and play a role in the rejection of organs or allogenic cells during organ transplantation and cell therapy. B2M is an attractive target to reduce the immunogenicity of iPS cell-derived allogenic cell therapies.

References

Cong L., et al., 2013 Science. 339(6121):819-23.  
Gerace D., et al., 2023 Cell Reports Medicine 4: 100879
Jinek M., et al., 2012 Science. 337(6096):816-21.
Mali P., et al., 2013 Science. 339(6121):823-6.
Lanza R., et al., 2019 Nat Rev Immunol 19: 723-733.
Takahashi K., et al., 2007 Cell. 131(5):861–872.
Yang L., et al., 2013 Nucleic Acids Res. 41(19):9049-61